Lenalidomide Krka (lenalidomide)

Adverse Event (AE) Form

This form must be returned to KRKA, d.d., Novo mesto; Telephone 3: +353 1 413 3710; Email⊠: pharmacovigilance.IE@krka.biz

For Krka use onl	•	VVVV					Case no:					
Received by:	00 141141											
Report type:			□ New					☐ Follow up				
Source: literature		terature		☐ Healt	h	□ P	☐ Patient		Other (sepecify)			
For studies enter:			profe Protocol no	ssional	Site no) no:		Patient no:				
				Trotocorne	J. JILE		110.					
Patient Data		Data of hinth.		0.07	۸	\A/=:= -	+ /l-~\·		11a:ath/aaa\.		Ca	
Initials:		Date of birth: DD MM		YY Age:		Weight (kg):			Heigth(cm):		Sex:	
Suspected Drug												
Drug, Dosage-form, Strength, Route (eg. Tab 5mg, oral)		Dose & frequency	Lot/ Bato	ch no. start date			Therapy end date				Indication for use of drug	
				DD/MM/YYY			DD / MM / YYYY					
					DD/MM/YYYY		DD/MM/YYYY					
					DD/MM/YYY	Y	DD / MM / YYYY					
					DD / MM / YYY	Y	DD / MM / YYYY					
					DD/MM/YYY	Y	DD/MM/YYYY					
Action taken												
□ None □ L		□ Unknow	n		☐ Dose decreased, specify		☐ Dose increased, specify		☐ Permai discont	•	☐ Temporarily interrupted	
Adverse Event Event			on-set date: DD/MM/YYYY Event stop			top date	: DD/MM/YYYY		Or ongoing at time of reporting (If less than 24 hours):HOUR/MIN			
Description of Ad	dverse E	vent (provide d	iagnosis if	available) -syi	mptoms and tre	eatment:	:					
Outcome of Adverse Event		☐ Recovered [☐ Recovered with sequelae		ae [☐ Not recove	ered		□ Unknown		
		□ Death □		Date of death:DD/MM/YYYY		C	Cause(s) of death:					
		Did the event hospitalisatio			F. C. P. C. C. G. C.		If autopsy is performed please forward report. Please attach relevant clinical laboratory assessments to confirm the event					
Medical History												
☐ Yes, please☐ None☐ Unknown	specify											
Other Medicatio	on (Med	ication taken in	the last 3	months prior	r to the event)							
Drug, Dosage-form, Strength, Route (eg. Tab 5mg, oral		5mg, oral)	Dose & frequency		Therapy start date:		Therapy end date:		Indic	Indication for use of drug		
					DD/MM/YYYY		DD/MM/YYYY DD/MM/YYYY					
					DD/MM/YYYY DD/MM/YYYY		DD/MM/YYYY					
			DD/MM/YY			DD/MM/YYYY						
					DD/MM/YY\		DD/MM/\					
Has the patient discussed this event with their healthcare professional?			□ No □ If yes, would you please provide their healthcare professional's contact information below?									

□ Unknown									
Healthcare professional's contact information									
Name:	Phone:								
Address:	Email:								
	Fax:								
Pharmacy Name (if applicable):									
Name:	Email:								
Reporter details									
Profession:	Phone:								
Name:	Email:								
Address:	Fax:								
Signature:	Date of AE awareness: DD/MM//YYYY								

Data Privacy Notice

We would like to notify you that you will share your personal data (aggregated anonymised patient limited data e.g., patient intials, date of birth) with KRKA SUBSIDIARY when you'll report adverse reaction or ask a question about the safety of our medicine. Because of the new EU data protection legislation we have to inform you that:

- We will process your data only for these purposes.
- That we have an obligation to process them and to store them permanently according to legislation governing medicinal products.
- Personal data protection policy and the rights of individuals are available on our website (www.krka/biz).